Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 7/20 | 0.54 |
| ▸ | TRPA1 | O75762 | 2/20 | 0.34 |
| ▸ | CYP11B1 | P15538 | 4/20 | 0.34 |
| ▸ | CYP11B2 | P19099 | 4/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.33 |
| ▸ | HPGD | P15428 | 2/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7215187 | 0.86 | PARP1 (0.37) | PARP1KDM4EALDH1A1HPGDTSHR | |
| SCHEMBL7215155 | 0.74 | PARP1 (0.38) | PARP1KDM4EMAPK8 | |
| SCHEMBL17978285 | 0.73 | PARP1 (0.84) | PARP1HSD17B10 | |
| Hydrochloric Acid SCHEMBL17978158 | 0.72 | PARP1 (0.81) | PARP1HSD17B10 | |
| SCHEMBL1502069 | 0.70 | PARP1 (1.00) | PARP1KDM4EALDH1A1HPGDMAPT | |
| SCHEMBL1520075 | 0.70 | PARP1 (0.64) | PARP1TRPA1CYP11B1CYP11B2KDM4E | |
| SCHEMBL8079405 | 0.70 | PARP1 (0.46) | PARP1TRPA1CYP11B1CYP11B2KDM4E | |
| Oxalic Acid SCHEMBL17978250 | 0.67 | PARP1 (0.90) | PARP1 | |
| Cadaverine Tartrate SCHEMBL20968877 | 0.66 | PARP1 (0.68) | PARP1HSD17B10 | |
| SCHEMBL19519485 | 0.66 | ALDH1A1 (0.40) | PARP1KDM4EALDH1A1HPGDMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6576766-B1 | Competitive binding of phosphotyrosine-containing protein; veterinary medicine | ARIAD PHARMACEUTICALS, INC. | 2003-06-10 | — | — | US | disclosed |
| US-6573295-B2 | Treating proliferative diseases, cancer, restenosis, osteoporosis, inflammation, aIlergies, or cardiovascular disease. | ARIAD PHARMACEUTICALS, INC. | 2003-06-03 | — | — | US | disclosed |
| US-6482852-B2 | UE TREATING PROLIFERATIVE DISEASE, CANCER, RESTENOSIS, OSTEOPOROSIS, INFLAMMATION, ALLERGIES, OR CARDIOVASCULAR DISEASE; INHIBITION OF SH2-MEDIATED SIGNALING | ARIAD PHARMACEUTICALS, INC. | 2002-11-19 | — | — | US | disclosed |
| US-20020137941-A1 | Ue treating proliferative disease, cancer, restenosis, osteoporosis, inflammation, allergies, or cardiovascular disease; inhibition of SH2-mediated signaling | ARIAD PHARMACEUTICALS, INC. | 2002-09-26 | — | — | US | disclosed |
| US-20020062031-A1 | Bicyclic signal transduction inhibitors, compositions containing them & uses thereof | SHAKESPEARE WILLIAM C (US) | 2002-05-23 | — | — | US | disclosed |
| EP-1129068-A1 | BICYCLIC SIGNAL TRANSDUCTION INHIBITORS, COMPOSITION CONTAINING THEM AND USES THEREOF | ARIAD PHARMACEUTICALS, INC. (US) | 2001-09-05 | — | — | EP | disclosed |
| WO-2000027802-A1 | BICYCLIC SIGNAL TRANSDUCTION INHIBITORS, COMPOSITIONS CONTAINING THEM & USES THEREOF | ARIAD PHARMACEUTICALS, INC. (US) | 2000-05-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020062031-A1 | Bicyclic signal transduction inhibitors, compositions containing them & uses thereof | ACP1, SRC, PPM1G | PARP1 2454/4885TRPA1 3843/4885CYP11B1 3133/4885 |
| US-20020137941-A1 | Ue treating proliferative disease, cancer, restenosis, osteoporosis, inflammation, allergies, or cardiovascular disease; inhibition of SH2-mediated signaling | GRB2, LCK, PTK2 | PARP1 3059/4885TRPA1 2969/4885CYP11B1 4137/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.